BWIN

ANALYST NOTE: BWIN (The Baldwin Insurance Group, Inc.) Date: 2026-06-13 Current Price: $20.24

1. Structural Readiness

State: Context-only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 6.3% (Very High)

Analysis:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Thesis: None

At this date, BWIN is not anchored to a named macro or secular thesis. The investment case is strictly tactical, driven by the quality of the immediate setup and the underlying business fundamentals rather than a broad thematic tailwind. The conviction must be derived entirely from the operational execution, financial metrics, and the structural quality of the price action as it develops. There is no external narrative to lean on; the trade relies on the company's ability to execute its stated strategy and the market's reaction to that execution.

3. The Business

Company Overview: The Baldwin Insurance Group, Inc. is an independent firm operating across the United States and internationally, representing over three million clients. The company is organized into three primary operating groups:

• Insurance Advisory Solutions (IAS): Provides commercial risk management, employee benefits, and private risk management for businesses and high-net-worth individuals.
• Underwriting, Capacity & Technology Solutions: Manufactures proprietary, technology-enabled insurance products (via the "Future" platform) and acts as a specialty wholesale broker and reinsurance broker.
• Mainstreet Insurance Solutions (MIS): Focuses on personal, commercial, and life/health insurance through sheltered distribution channels (e.g., new home builders, realtors).

Operational Highlights (as of Q1/Q2 2026):

• Financial Performance: In the quarter ended March 31, 2026, the company reported total revenue of $532 million, adjusted EBITDA of $137 million, and an adjusted EBITDA margin of 26%. Adjusted diluted EPS was $0.63.
• Growth Drivers: The company executed three partnerships with an aggregate purchase price of $1.6 billion in the first quarter. This drove a 29% year-over-year increase in commissions and fees, with $111.5 million attributed to partnership activity and $11.3 million to organic growth.
• Segment Performance:
• CAC (Capital Acquisition Group): Generated $38 million in new business (up 39% YoY) with total revenue of $92 million (up 27% YoY).
• Multifamily Business: Revenue grew 10% in the quarter.
• Juniper Re: Revenue grew over 90%, reflecting scale advantages in proprietary capacity.
• Cost Synergies: The company has actioned over $34 million in cost synergies, representing nearly 80% of its three-year $43 million target.
• Product Pipeline: Two new middle-market commercial lines products were launched in 2025, with several more slated for 2026.

Management Expectations (Q2 2026 Guidance): Management expects Q2 revenue to be between $485 million and $490 million, with organic revenue growth in the mid-single digits. Adjusted EBITDA is anticipated between $113 million and $118 million, with adjusted diluted EPS of $0.44 to $0.48.

4. Archetype and Conviction

Archetype: Growth Leader / Margin Inflector Valuation Context: The financial spine indicates a forward consensus EPS of $2.01 for FY1 and $2.52 for FY2. At a current price of $20.24, the stock trades at approximately 10x FY1 EPS and 8x FY2 EPS, suggesting a valuation that prices in significant growth acceleration.

Conviction Stack:

• Thesis Strength: Moderate. The lack of a named secular thesis limits the "story" but the tactical focus on execution is clear.
• Evidence Quality: High. The earnings transcript and SEC filings provide granular data on revenue drivers, synergy realization, and segment growth. The $1.6B in partnership activity is a material catalyst.
• Structural Quality: Mixed. While the business fundamentals show strong momentum (29% fee growth, 90% Juniper Re growth), the price structure is currently "Forming" with "Very High" volatility (6.3% ATR). The high volatility suggests the market is still digesting the recent partnership activity and earnings, preventing a clean structural setup.
• Setup Readiness: Low to Moderate. The setup is not yet confirmed. The "Forming" state implies the market is building a base, but the breakout has not fired.
• Rerating Potential: High. If the company continues to execute on its $43M synergy target and the partnership pipeline converts to sustained organic growth, the multiple could expand from the current ~10x FY1 level.

ATR Context: The current ATR of 6.3% is in the "very high" bucket. Historically, this level of volatility can lead to false breakouts or deep pullbacks. It requires careful position sizing and a wider stop distance if a setup were to form, but currently, it reinforces the "Forming" classification where the structure is not yet stable enough for a conservative entry.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Fundamental: A miss on the Q2 guidance (Revenue < $485M or EPS < $0.44) or a significant slowdown in the pace of partnership acquisitions would weaken the growth narrative.
• Synergy: Failure to close the remaining 20% of the $43M synergy target by the end of the three-year cycle.

Strengtheners:

• Fundamental: Acceleration in organic growth beyond the "mid-single digits" guidance or successful launch of the 2026 product pipeline.
• Strategic: Announcement of additional high-quality partnerships or expansion of the "Future" platform's proprietary product adoption.

Evidence Gaps:

• Debt Servicing: While management notes interest expense will grow due to borrowings for partnerships, the specific impact on net income margins is not detailed beyond the guidance range.
• Long-term Retention: Data on the retention rates of the acquired partnership revenue is not explicitly provided in the current evidence set.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Q1 revenue of $532M with 29% fee growth driven by $1.6B in partnerships; Juniper Re revenue up >90%; 80% of $43M synergy target achieved. Key risks: Very high ATR (6.3%) indicates unstable price structure; guidance miss on Q2 organic growth; integration risk from rapid partnership acquisitions. Sizing hint: Position size should be reduced relative to a confirmed breakout due to the "forming" state and elevated volatility. Expected path: Management expects mid-single digit organic growth and $113-118M EBITDA in Q2; price likely to consolidate before a directional move if guidance is met. Expected horizon: 3 to 6 months for structural confirmation or invalidation.